{"classes":[{"categories":[{"measurements":[{"comment":"The was not reached and therefore the upper confidence bound could not be estimated.","groupId":"OG001","lowerLimit":"9.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"comment":"Confidence interval cannot be calculated when there is only one subject.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"19.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.0","upperLimit":"24.6","value":"18.0"},{"groupId":"OG001","lowerLimit":"10.6","upperLimit":"24.1","value":"15.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"13.2","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Unknown or Not Reported"},{"categories":[{"measurements":[{"comment":"The median was not reached and therefore the upper confidence bound could not be estimated.","groupId":"OG000","lowerLimit":"49.4","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Asian"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"NIH-required analysis. A disease event is defined as local/regional persistence or recurrence of the cancer under study, distant metastases, a new second primary cancer, or death due to any cause. Participants undergoing surgery who had an R2 resection and participants not undergoing surgery who had a positive endoscopic biopsy or no biopsy at all were considered to have local persistence of disease. Disease-free survival time is defined as time from randomization to the date of first disease event or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. Analysis was to occur after 162 events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab (Arm 1)"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation (Arm 2)"}],"paramType":"MEDIAN","populationDescription":"Eligible randomized participants. Data were stratified by race.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 8.0 years.","title":"Disease-free Survival (DFS) by Race","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}